SCHEMBL1760221

SCHEMBL1760221

N#Cc1ccc(C(=O)Nc2ccc(CCC3COC(N)=N3)cc2)cn1.NC1=NC(CCc2ccc(NC(=O)c3cc(F)cnc3F)cc2)CO1.NC1=NC(CCc2ccc(NC(=O)c3ccc(F)nc3F)cc2)CO1.NC1=NC(CCc2ccc(NC(=O)c3cnc(Cl)c(Cl)c3)cc2)CO1

nearest known ligand 0.43

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 1/20 0.36
KCNH2 Q12809 1/20 0.36
TAAR1 Q96RJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1760220 1.00 SLC6A3 (0.36) SLC6A3KCNH2TAAR1
SCHEMBL1759829 0.93
SCHEMBL1759830 0.93
SCHEMBL1760029 0.80
SCHEMBL1760031 0.80
SCHEMBL1759682 0.79
SCHEMBL1759686 0.79
SCHEMBL1759636 0.79 NPC1 (0.51)
SCHEMBL1759634 0.79 NPC1 (0.51)
SCHEMBL1760283 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2499121-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS. F. Hoffmann-La Roche AG (CH) 2012-09-19 EP claimed
WO-2011057973-A1 OXAZOLINE DERIVATIVES FOR TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2011-05-19 WO claimed